Search Result

Results for "

p-gp

" in MedChemExpress (MCE) Product Catalog:

By Targets:	P-glycoprotein (105) 5-HT Receptor (1) Adrenergic Receptor (1) Akt (3) AMPK (1) Amylases (1) Amyloid-β (1) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (6) Apoptosis (16) Atg8/LC3 (1) Autophagy (7) Bacterial (6) Bcl-2 Family (2) BCRP (13) Beta-secretase (2) c-Met/HGFR (2) Calcium Channel (6) Cannabinoid Receptor (1) Carbonic Anhydrase (1) Caspase (2) CCR (1) CDK (1) Cytochrome P450 (15) DNA/RNA Synthesis (1) Dopamine β-hydroxylase (1) Drug Metabolite (2) Endogenous Metabolite (7) ERK (1) Ferroptosis (1) FGFR (3) Glycosidase (1) HBV (1) HCV Protease (1) Hedgehog (2) HIV (4) HIV Protease (4) iGluR (3) Interleukin Related (1) Liposome (1) mAChR (1) Microtubule/Tubulin (2) Mitochondrial Metabolism (1) NF-κB (4) Opioid Receptor (1) p38 MAPK (2) p62 (1) Parasite (4) PARP (2) Potassium Channel (1) PPAR (2) Reactive Oxygen Species (1) ROS Kinase (1) SARS-CoV (6) Serotonin Transporter (1) Small Interfering RNA (siRNA) (1) STAT (1) TAM Receptor (2) TNF Receptor (1) Topoisomerase (1) Wee1 (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (110) Cardiovascular Disease (9) Endocrinology (1) Infection (16) Inflammation/Immunology (11) Metabolic Disease (11) Neurological Disease (14)
Oligonucleotides:	Pre-designed siRNA Sets (1) Phospholipids (1) siRNAs (1)

151

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-157483

P-gp inhibitor 18	P-glycoprotein	Cancer
P-gp inhibitor 18 (compound 6G) is a potent inhibitor of *P-gp. P-gp* inhibitor 18 inhibits rhodamine 123 efflux in the P-gp overexpressed leukemia cells, K562/Dox .

HY-149981

P-gp inhibitor 13	P-glycoprotein	Cancer
P-gp inhibitor 13 is a *P-gp* inhibitor. P-gp inhibitor 13 can reverse P-glycoprotein-mediated paclitaxel resistance in A2780/T cell. P-gp inhibitor 13 can be used for the research of advanced acute myeloid leukemia .

HY-144366

P-gp inhibitor 3	P-glycoprotein	Cancer
P-gp inhibitor 3 is an effective P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 3 inhibits the efflux function of P-gp by activating P-gp ATPase. P-gp inhibitor 3 has relatively stronger multidrug resistance (MDR) reversal ability and enhances the anti-tumor activity of Paclitaxel .

HY-162040

P-gp inhibitor 17	P-glycoprotein	Cancer
P-gp inhibitor 17 (compound 2g) is a *P-gp* inhibitor directly interacted with the transmembrane domain of *P-gp. P-gp* inhibitor 17 can be used for P-gp-mediated multidrug-resistant in tumor cells study .

HY-162822

P-gp modulator-5	P-glycoprotein	Cancer
P-gp modulator-5 (compound 25) is a modulator of *P-gp* and can inhibit the proliferation of multidrug resistant (MDR) tumors. P-gp modulator-5 inhibits the activity of drug efflux pumps in MDR cells, leading to a large accumulation of ROS and altered cell cycle profiles .

HY-161645

P-gp modulator-4	P-glycoprotein	Cancer
P-gp modulator-4 (compound 4c) inhibits the efflux function of P-glycoprotein (P-gp). P-gp modulator-4 shows multidrug resistance (MDR) in cancer reversal activity (IC₅₀ of Paclitaxel (HY-B0015) = 8.80, reversal fold = 211.8) .

HY-161260

P-gp inhibitor 20	P-glycoprotein	Cancer
P-gp inhibitor 20 (compound H27) is a low cytotoxicity P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 20 inhibits the efflux function of P-gp in a dose-dependent manner (without affecting the expression of P-gp), thereby reversing the multidrug resistance (MDR) of MCF-7/ADR cells, with an IC₅₀ value of 46.6 nM. P-gp inhibitor 20 can be used for cancer research .

HY-168008

P-gp inhibitor 25	P-glycoprotein	Cancer
P-gp inhibitor 25 (compound 16c) is a *P-gp* inhibitor. P-gp inhibitor 25 can enhance the oral absorption of paclitaxel (HY-B0015). P-gp inhibitor 25 can be used in anti-cancer research .

HY-149813

P-gp inhibitor 14	P-glycoprotein	Cancer
P-gp inhibitor 14 (Compound 8a) is a high affinity *P-gp* inhibitor. P-gp inhibitor 14 reverses P-gp-mediated multidrug resistance (EC₅₀=48.74 nM). P-gp inhibitor 14 has a weak inhibitory effect on CYP3A4 activity .

HY-N144114

P-gp inhibitor 2	P-glycoprotein	Cancer
P-gp inhibitor 2 is a potent *P-gp* inhibitor. P-gp inhibitor 2 shows reverse Doxorubicin resistance (IC₅₀=0.22 µM) in P-gp overexpressing human colorectal carcinoma cells (SW600 Ad300) .

HY-168186

P-gp inhibitor 26	P-glycoprotein	Cancer
P-gp inhibitor 26 (Compound 7i) is a potent *P-gp* inhibitor. P-gp inhibitor 26 potently reverses P-gp-mediated multidrug resistance in K562/A02 cells .

HY-159085

P-gp inhibitor 24	P-glycoprotein	Cancer
P-gp inhibitor 24 (Compound 10) is an inhibitor for P-glycoprotein (P-gp)), that inhibits the P-gp mediated fluorescent dye efflux. P-gp inhibitor 24 exhibits multidrug resistance (MDR) reversal effect, enhances the cytotoxicity of Vincristine (HY-N0488) and Etoposide (HY-13629) in cancer cells .

HY-146117

P-gp modulator 2	P-glycoprotein	Cancer
P-gp modulator 2 (Compound 27) is a potent, competitive, allosteric P-glycoprotein (P-gp) modulator .

HY-146118

P-gp modulator 3	P-glycoprotein	Cancer
P-gp modulator 3 (Compound 37) is a potent, competitive, allosteric P-glycoprotein (P-gp) modulator .

HY-162447

P-gp inhibitor 22	P-glycoprotein Apoptosis	Cancer
P-gp inhibitor 22 is a P-glycoprotein (P-gp) inhibitor that effectively inhibits P-pg and efflux function. P-gp inhibitor 22 induces apoptosis and accumulation of MCF-7/ADR cells processed in the S phase .

HY-157484

P-gp inhibitor 19	P-glycoprotein	Cancer
P-gp inhibitor 19 (Compound 6i) is a P-gp inhibitor. P-gp inhibitor 19 can inhibit the efflux of rhodamine 123 (HY-D0816) in P-gp-overexpressing leukemia cells K562/Dox and also restore the sensitivity of DOX-resistant cells .

HY-155032

P-gp inhibitor 15	P-glycoprotein	Cancer
P-gp inhibitor 15 (compound 7a) is a nonsubstrate inhibitor of P-glycoprotein (Pgp). P-gp inhibitor 15 inhibits Pgp-ATPase activity，and interfers Pgp-mediated Rhodamine123 efflux. P-gp inhibitor 15 also enhances the inhibitory efficacy of Paclitaxel (HY-B0015)，inhibits tumor progress in nude mice KBV xenograft tumors model .

HY-158435

P-gp inhibitor 23	P-glycoprotein Cytochrome P450	Cancer
P-gp inhibitor 23 (compound 14F) is a potent inhibitor of *P-gp* and CYP3A4, with the EC₅₀ and IC₅₀ of 28 nM and 223 nM, respectively .

HY-162396

P-gp inhibitor 21	P-glycoprotein	Cancer
P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .

HY-150565

P-gp inhibitor 5	P-glycoprotein	Cancer
P-gp inhibitor 5 is a potent P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 5 has antiproliferative activity against certain cancer cell lines. P-gp inhibitor 5 is effective in reversing the multidrug resistance (MDR) phenotype in ABCB1/Flp-In ^TM-293 and KBvin cells by restoring their sensitivity to Vincristine (HY-N0488A) and Paclitaxel (HY-B0015) .

HY-157330

P-gp inhibitor 16	P-glycoprotein Apoptosis	Cancer
P-gp inhibitor 16 (compound 14) is a p-glycoprotein inhibitor. P-gp inhibitor 16 significantly increases Doxorubicin-induced apoptosis and shows anticancer effects .

HY-168711

P-gp inhibitor 27	P-glycoprotein	Cancer
P-gp inhibitor 27 (Compound D2) is an inhibitor for P-glycoprotein (P-gp), that downregulates the expression of P-gp and MRP1, increases the Rh123 accumulation in A2780/T cell, and reverses multidrug resistance to Paclitaxel (HY-B0015) (EC₅₀ is 88 nM) and Cisplatin (HY-17394) .

HY-112912

P-gp modulator 1	P-glycoprotein	Cancer
P-gp modulator 1 is a high affinity, orally available modulator of P-glycoprotein (Pgp), can reverse the Pgp-mediated multidrug resistance ((MDR) .

HY-146391

P-gp inhibitor 4	P-glycoprotein	Cancer
P-gp inhibitor 4 (Compound 8b) is a selective P-glycoprotein modulator with an EC₅₀ of 94 nM. P-gp inhibitor 4 increases agent transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells .

HY-101791

P-gp inhibitor 1	P-glycoprotein	Cancer
P-gp inhibitor 1 is a novel inhibitor reversing P-glycoprotein-mediated multidrug resistance.

HY-144393

P-gp/BCRP-IN-1	BCRP	Cancer
P-gp/BCRP-IN-1 (compound 19) is a potential, relatively safe, orally active and efficient efflux transporter (P-gp and BCRP) inhibitor. P-gp/BCRP-IN-1 exerts resistance reversal by inhibiting the efflux function of *P-gp* and BCRP. P-gp/BCRP-IN-1 can overcome the resistance and improve the oral bioavailability of PTX (Paclitaxel) .

HY-161776

P-gp/CDK2-IN-1	P-glycoprotein CDK	Cancer
P-gp/CDK2-IN-1 (Compound 4j) is an inhibitor for is inhibitor for P-glycoprotein (P-gp) and for cyclin-dependent kinase-2 (CDK2). P-gp/CDK2-IN-1 inhibits the proliferation of cancer cells SW-480 and MCF-7 wit IC₅₀ of 38.6 μM and 26.6 μM. P-gp/CDK2-IN-1 exhibits antioxidant efficacy with EC₅₀ of 580 μM in DPPH experiment .

HY-119823

PGP-4008	P-glycoprotein	Cancer
PGP-4008 is a specific P-glycoprotein (Pgp) inhibitor. PGP-4008 inhibits tumor growth in a murine syngeneic Pgp-mediated multiple agent resistance (MDR) solid tumor model when given in combination with Doxorubicin .

HY-155152

P-gp/BCRP-IN-2	P-glycoprotein BCRP	Cancer
P-gp/BCRP-IN-2 (compound 15) is an oxadiazole derivative and a dual inhibitor of the ABC transporter P-glycoprotein (IC₅₀: 1.6 nM) and BCRP (IC₅₀: 600 nM). P-gp/BCRP-IN-2 also enhances the anti-proliferative effects of Doxorubicin (HY-15142A) in drug-resistant human adenocarcinoma colon cancer cell lines HT29/DX and MDCK-MDR1 cells .

HY-RS10394

PGP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PGP Human Pre-designed siRNA Set A contains three designed siRNAs for PGP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PGP Human Pre-designed siRNA Set A PGP Human Pre-designed siRNA Set A

HY-N7120

Penicillin G procaine hydrate Pgp hydrate	Bacterial Antibiotic	Infection
Penicillin G Procaine hydrate (PGP hydrate), a β-lactam antibiotic, is a crystalline complex produced by chemically combining penicillin G with procaine .

HY-159614

PG-PS	TNF Receptor Interleukin Related	Inflammation/Immunology
PG-PS is a complex composed of streptococcal cell wall peptidoglycans and polysaccharides with pro-inflammatory and arthritis-inducing activity. PG-PS can be used to establish arthritis models. PG-PS can cause inflammation and joint damage, increase the expression of pro-inflammatory cytokines (TNF-α and IL-1β), and disrupt cellular redox balance .

HY-162369

PID-9	P-glycoprotein	Cancer
PID-9 is a P-glycoprotein inhibitor. PID-9 has multidrug resistance (MDR) reversal activity (IC₅₀ = 0.1338 μM) and low toxicity. PID-9 inhibits the transport function of P-gp without downregulating P-gp expression .

HY-W009141

1-Monopalmitin Glyceryl palmitate	P-glycoprotein	Cancer
1-Monopalmitin, a bitter melon extract, inhibits the P-glycoprotein (P-gp) activity in intestinal Caco-2 cells .

HY-N7305

Jatrophane 5	P-glycoprotein	Cancer
Jatrophane 5 is a natural product of Jatropha carcas L. Jatrophane 5 has powerful inhibition of *P-gp*, higher than R(+)-verapamil (HY-14275) and Tariquidar (HY-10550) in colorectal multi-drug resistant cells (DLD1-TxR) .

HY-121247

Bromotetrandrine 5-Bromotetrandrine; BrTet; W198	P-glycoprotein	Cancer
Bromotetrandrine is a potent inhibitor of P-glycoprotein (P-gp)-mediated multidrug resistance (MDR). Bromotetrandrine shows significant MDR reversal activity in vitro and in vivo, which may be related to the inhibition of P-gp overexpression and the increase in intracellular accumulation of anticancer agents. Bromotetrandrine is a brominated derivative of tetrandrine, which is promising for MDR modulator for tumor assessment .

HY-108286

Talinolol Cordanum	Adrenergic Receptor	Cardiovascular Disease
Talinolol (Cordanum) is a long-acting, cardioselective β1-adrenergic receptor blocker. Talinolol exhibits cardioprotective and antihypertensive activities. Talinolol is also a well-known and frequently used probe substrate for P-glycoprotein (P-gp) activity .

HY-146096

RMS3	P-glycoprotein Apoptosis	Cancer
RMS3, a tetrandrine analogue, is a potent P-glycoprotein (P-gp) inhibitor. RMS3 has markedly antiproliferative and cytotoxic effects on cancer cells. RMS3 causes PARP cleavage, a marker for cells undergoing apoptosis. RMS3 has strong anticancer property .

HY-W009141R

1-Monopalmitin (Standard)	P-glycoprotein	Cancer
1-Monopalmitin (Standard) is the analytical standard of 1-Monopalmitin. This product is intended for research and analytical applications. 1-Monopalmitin, a bitter melon extract, inhibits the P-glycoprotein (P-gp) activity in intestinal Caco-2 cells .

HY-N6932

Voacamine	Cannabinoid Receptor P-glycoprotein	Metabolic Disease Cancer
Voacamine, an indole alkaloid, exhibits potent cannabinoid CB1 receptor antagonistic activity . Voacamine also inhibits P-glycoprotein (P-gp) action in multidrug-resistant tumor cells .

HY-U00247

MCI826	P-glycoprotein	Cancer
MCI826 is a P-glycoprotein (P-gp) antagonist.

HY-A0064

Verapamil hydrochloride Maximum Cited Publications 57 Publications Verification (±)-Verapamil hydrochloride; CP-16533-1 hydrochloride	Calcium Channel P-glycoprotein Cytochrome P450	Cardiovascular Disease Cancer
Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research .

HY-14275

Verapamil Maximum Cited Publications 57 Publications Verification (±)-Verapamil; CP-16533-1	Calcium Channel P-glycoprotein Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research .

HY-N10562

Mutabilol	P-glycoprotein	Cancer
Mutabilol (compound 1) is a potent p-glycoprotein (P-gp) regulator. Mutabilol is a nature product could be isolated from Plectranthus mutabilis leaves. Mutabilol increases the P-gp expression in NCI-H460/R cells .

HY-19642A

Glesatinib hydrochloride 2 Publications Verification MGCD265 hydrochloride	TAM Receptor c-Met/HGFR	Cancer
Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent MET/SMO dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .

HY-19642

Glesatinib MGCD265	TAM Receptor c-Met/HGFR	Cancer
Glesatinib (MGCD265) is an orally active, potent MET/SMO dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .

HY-W700684

N-Didesmethyl Loperamide R 21345	Others	Others
N-Didesmethyl Loperamide is a metabolite of Loperamide; a new and improved PET radiotracer for imaging P-gp function.

HY-B0777

Moxidectin 1 Publications Verification CL301423	Antibiotic BCRP P-glycoprotein Parasite	Infection
Moxidectin (CL301423) is an orally active macrolide (ML) anthelmintic for the prevention and control of heartworms and roundworms. Moxidectin is also a substrate of BCRP and P-glycoprotein (P-gp) in vivo, and is secreted into breast milk and effluxed from the host and parasite mediated by Bcrp1 and P-gp. This may be related to the presence of chemical residues in milk .

HY-149360

P-gb-IN-1	P-glycoprotein	Cancer
P-gb-IN-1 (compound Ⅲ-8), a 2,5-disubstituted furan derivative, is a highly effective, broadspectrum P-glycoprotein (P-gp) inhibitor. P-gb-IN-1 displayed the reversal activity by inhibiting P-gp efflux. P-gb-IN-1 has a potent affinity to P-gp by forming H-bond interactions with residues Asn 721 and Met 986. P-gb-IN-1 possesses broad-spectrum reversal activity and low toxicity in MCF-7/ADR cells .

HY-N2453

Convallatoxin	PPAR NF-κB P-glycoprotein	Inflammation/Immunology Cancer
Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties .

Cat. No.	Product Name

HY-L011

Membrane Transporter/Ion Channel Compound Library

1,591 compounds

Most of molecules enter or leave cells mainly via membrane transport proteins, which play important roles in several cellular functions, including cell metabolism, ion homeostasis, signal transduction, the recognition process in the immune system, energy transduction, etc. There are three major types of transport proteins, ATP-powered pumps, channel proteins and transporters. Transport proteins such as channels and transporters play important roles in the maintenance of intracellular homeostasis, and mutations in these transport protein genes have been identified in the pathogenesis of a number of hereditary diseases. In the central nervous system, ion channels have been linked to, but not limited to, many diseases such asataxias, paralyses, epilepsies, and deafness. This indicates the roles of ion channels in the initiation and coordination of movement, sensory perception, and encoding and processing of information. Ion channels are a major class of drug targets in drug development.

MCE designs a unique collection of 1,591 smal-molecule modulators that can be used for the research of Ion Channel and Membrane Transporter or high throughput screening (HTS) related drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-162396

P-gp inhibitor 21	P-glycoprotein	Cancer
P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .

Species:	Human (5) Mouse (1) Rat (1) Cynomolgus (1)
Tag:	His (6) Avi (1) Fc (2)
Source:	HEK293 (5) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P71096

	UCHL1 Protein, Human (His, solution) Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L1; UCH-L1; Neuron Cytoplasmic Protein 9.5; Pgp 9.5; Pgp9.5; Ubiquitin Thioesterase L1; UCHL1	Human	E. coli

HY-P73466

	UCHL1 Protein, Mouse (His) Ubiquitin carboxyl-terminal hydrolase isozyme L1; UCH-L1; Uchl1; Pgp9.5	Mouse	E. coli
	UCHL1 Protein, a ubiquitin carboxyl-terminal hydrolase, plays a crucial role in protein degradation and regulation of cellular processes.It is involved in maintaining neuronal integrity and has been linked to neurodegenerative diseases.UCHL1 Protein's potential as a biomarker and therapeutic target in neurodegenerative disorders makes it a subject of intense research in the field of neuroscience.UCHL1 Protein, Mouse (His) is the recombinant mouse-derived UCHL1 protein, expressed by E.coli , with N-His labeled tag.

HY-P74483

	UCHL1 Protein, Rat (His) Ubiquitin carboxyl-terminal hydrolase isozyme L1; UCH-L1; Uchl1; Pgp9.5	Rat	E. coli
	The UCHL1 protein is a ubiquitin proteolytic enzyme essential for processing ubiquitin precursors and hydrolyzing ubiquitinated proteins. As a thiol protease, it specifically cleaves the C-terminal glycine of ubiquitin. UCHL1 Protein, Rat (His) is the recombinant rat-derived UCHL1 protein, expressed by E. coli , with N-10*His labeled tag. The total length of UCHL1 Protein, Rat (His) is 222 a.a., with molecular weight of ~28 kDa.

HY-P70507

	CD44 Protein, Human (HEK293, His) CD44 Antigen; CDw44; Epican; Extracellular Matrix Receptor III; ECMR-III; gp90 Lymphocyte Homing/Adhesion Receptor; HUTCH-I; Heparan Sulfate Proteoglycan; Hermes Antigen; Hyaluronate Receptor; Phagocytic Glycoprotein 1; Pgp-1; Phagocytic Glycoprotein I; Pgp-I; CD44; LHR	Human	HEK293
	CD44 Protein is a type of cell surface receptor protein. CD44 Protein mediates various signaling pathways, including protein kinases, changes in the cytoskeleton, intracellular pathways, proteases, and transcription factors, which promote cancer cell division, proliferation, invasion, angiogenesis, and metabolic changes. The expression level of CD44 Protein is positively correlated with the malignancy and invasiveness of glioblastoma. CD44 Protein, Human (HEK293, His) is a recombinant CD44 protein tagged with a C-6*His label, expressed by HEK293. CD44 Protein, Human (HEK293, His) consists of 200 amino acids and has a molecular weight of 38-50 kDa.

HY-P700402

	CD44 Protein, Human (Biotinylated, HEK293) CD44 Antigen; CDw44; Epican; Extracellular Matrix Receptor III; ECMR-III; gp90 Lymphocyte Homing/Adhesion Receptor; HUTCH-I; Heparan Sulfate Proteoglycan; Hermes Antigen; Hyaluronate Receptor; Phagocytic Glycoprotein 1; Pgp-1; Phagocytic Glycoprotein I; Pgp-I; CD44; LHR	Human	HEK293
	CD44 is a cell surface receptor that plays a key role in calcium mobilization and actin-mediated cytoskeletal reorganization, cell migration, and adhesion. CD44 Protein, Human (Biotinylated, HEK293) is the recombinant human-derived CD44 protein, expressed by HEK293 , with C-Avi, C-mFc labeled tag. The total length of CD44 Protein, Human (Biotinylated, HEK293) is 200 a.a., with molecular weight of 51 kDa.

HY-P700967

	CD44 Protein, Human (242a.a, HEK293, His) CD44; CDw44; Epican; ECMR-III; LHR; MDU2; MDU3; MIC4; Pgp-I; CSPG8; HCELL; HUTCH-I; IN; MC56	Human	HEK293
	CD44 is a cell surface receptor that plays a key role in calcium mobilization and actin-mediated cytoskeletal reorganization, cell migration, and adhesion. CD44 Protein, Human (242a.a, HEK293, His) is a recombinant protein dimer complex containing human-derived CD44 protein, expressed by HEK293 , with C-His labeled tag. CD44 Protein, Human (242a.a, HEK293, His), has molecular weight of 45-68 kDa.

HY-P700439

	CD44 Protein, Macaca fascicularis (HEK293, His) CD44 Antigen; CDw44; Epican; Extracellular Matrix Receptor III; ECMR-III; gp90 Lymphocyte Homing/Adhesion Receptor; HUTCH-I; Heparan Sulfate Proteoglycan; Hermes Antigen; Hyaluronate Receptor; Phagocytic Glycoprotein 1; Pgp-1; Phagocytic Glycoprotein I; Pgp-I; CD44; LHR	Cynomolgus	HEK293
	The CD44 protein is characterized by a lack of conserved residues critical for annotation of propagation signatures. This defective residue in CD44 prevents the propagation of specific functional features associated with this protein. CD44 Protein, Macaca fascicularis (HEK293, His) is the recombinant cynomolgus-derived CD44 protein, expressed by HEK293 , with C-10*His labeled tag. The total length of CD44 Protein, Macaca fascicularis (HEK293, His) is 630 a.a., with molecular weight of 71.6 kDa.

HY-P700966

	CD44 Protein, Human (242a.a, HEK293, hFc) CD44; CDw44; Epican; ECMR-III; LHR; MDU2; MDU3; MIC4; Pgp-I; CSPG8; HCELL; HUTCH-I; IN; MC56	Human	HEK293
	CD44 is a cell surface receptor that plays a key role in calcium mobilization and actin-mediated cytoskeletal reorganization, cell migration, and adhesion. CD44 Protein, Human (242a.a, HEK293, hFc) is a recombinant protein dimer complex containing human-derived CD44 protein, expressed by HEK293 , with C-hFc labeled tag. CD44 Protein, Human (242a.a, HEK293, hFc), has molecular weight of 70-100 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80785

	PGP9.5 Antibody UCHL1 / Pgp9.5; UCHL1; B220; CD 45; CD45; cd45 antigen; ec3.1.3.48; gp 180; gp180; Human homolog of severe combined immunodeficiency due to PTPRC deficiency; L CA; L-CA; lca; Leukocyte common antigen; LY 5; LY5; Protein tyrosine phosphatase receptor type	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat
	PGP9.5 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 25 kDa, targeting to PGP9.5. It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P80527

	ABCB5 Antibody (YA836) ABCB5 P-gp; ATP binding cassette sub family B (MDR/TAP) member 5; P glycoprotein ABCB5	WB, ICC/IF	Human
	ABCB5 Antibody (YA836) is a non-conjugated and Mouse origined monoclonal antibody about 139 kDa, targeting to ABCB5 (8D2). It can be used for WB,ICC/IF assays with tag free, in the background of Human.

HY-P80772

	P Glycoprotein Antibody p-pg; Pgp; ABCB1; MDR1; PGY1; Multidrug resistance protein 1; ATP-binding cassette sub-family B member 1; P-glycoprotein 1; CD antigen CD243	WB	Human
	P Glycoprotein Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 141 kDa, targeting to P Glycoprotein. It can be used for WB assays with tag free, in the background of Human.

HY-P80062

	CD44 Antibody LHR antibody; BA-1 antibody; CD 44 antibody; CD44 antibody; CD44 antigen antibody; CD44 molecule (Indian blood group) antibody; CD44 molecule antibody; CD44_HUMAN antibody; CDw44 antibody; Cell surface glycoprotein CD44 antibody; chondroitin sulfate proteoglycan 8 antibody; CSPG8 antibody; ECMR-III antibody; Epican antibody; Extracellular matrix receptor III antibody; gp90 lymphocyte homing/adhesion receptor antibody; HCELL antibody; hematopoietic cell E- and L-selectin ligand antibody; Heparan sulfate proteoglycan antibody; Hermes antigen antibody; homing function and Indian blood group system antibody; HSA antibody; HUTCH-I antibody; HUTCH1 antibody; Hyaluronate receptor antibody; IN antibody; MC56 antibody; MDU2 antibody; MDU3 antibody; MGC10468 antibody; MIC4 antibody; MUTCH1 antibody; Pgp-1 antibody; Pgp-I antibody; Pgp1 antibody; Phagocytic glycoprotein 1 antibody; Phagocytic glycoprotein I antibody; Soluble CD44 antibody;	WB, IHC-P, FC	Human, Mouse
	CD44 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 82 kDa, targeting to CD44. It can be used for WB,IHC-P,FC assays with tag free, in the background of Human, Mouse.